PF-Atlas › Clinical Trials › NCT02502097
A Study of Gefapixant in Participants With Idiopathic Pulmonary Fibrosis With Persistent Cough
Gefapixant · Phase 2
Registry ID
NCT02502097
Phase
Phase 2
Status
Completed
Drug / intervention
Gefapixant
Sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Start
2015-08-26
About this trial
Gefapixant is evaluated in NCT02502097, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02502097 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.